Decitabine
Small molecule targets DNMT1, DNMT3A, TUSC3 via inhibition / activation
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Dacogen | — | 2012-09-20 | europa.eu ↗ |
| Label expansion | US (FDA) | DACOGEN | — | 2010-03-11 | fda.gov ↗ |
| Approved | US (FDA) | DACOGEN | — | 2006-05-02 | fda.gov ↗ |
Trials 406 · started per year
Also used as a comparator or background therapy in 77 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06499025 Background | Feb 2024 → Dec 2026 expected | acute myeloid leukemia with t(8;21)(q22;q22) translocation | BGI, China | Enrolling by invitation | No outcome recorded |
| Phase 120 trials | ||||||
| Phase 1 | NCT07177079 Background | Mar 2026 → Dec 2028 expected | acute myeloid leukemia | Kittika Poonsombudlert | Recruiting | No outcome recorded |
| Phase 1 | NCT07374029 Background | Feb 2026 → Oct 2027 expected | acute myeloid leukemia | David Avigan | Recruiting | No outcome recorded |
| Phase 1 | NCT07014462 Background | Sep 2025 → Jun 2029 expected | acute myeloid leukemia | University of Vermont | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06651866 Background | Dec 2024 → Dec 2026 expected | acute myeloid leukemia | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
| Phase 1 | NCT06401603 Background | Aug 2024 → Jan 2027 expected | Philadelphia-positive myelogenous leukemia, chronic myeloid leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05829226 Background | Dec 2022 → Dec 2025 | acute myeloid leukemia, myelodysplastic syndrome | PureTech | Completed | No outcome recorded |
| Phase 1 | NCT05190471 Background | Aug 2022 → Mar 2027 expected | acute myeloid leukemia | Bio-Path Holdings, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05222984 Background | Jul 2022 → Mar 2027 expected | acute myeloid leukemia | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05456269 Background | Jul 2022 → Aug 2023 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Racura Oncology Ltd | Withdrawn | No outcome recorded |
| Phase 1 | NCT03844815 Background | Nov 2019 → Dec 2027 expected | acute myeloid leukemia | University of Chicago | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03395873 Background | Jan 2018 → May 2019 | acute myeloid leukemia | Milton S. Hershey Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT03236857 Background | Nov 2017 → Apr 2023 | acute lymphoblastic leukemia, acute myeloid leukemia, neuroblastoma | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT03063944 Background | Mar 2017 → Jan 2024 | acute myeloid leukemia | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1 | NCT02954653 Comparator | Nov 2016 → Dec 2017 | acute myeloid leukemia | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT01483274 Background | Mar → Jun 2015 | acute myeloid leukemia | University of Louisville | Withdrawn | No outcome recorded |
| Phase 1 | NCT02093403 Background | Mar 2014 → Nov 2016 | acute myeloid leukemia | Bhavana Bhatnagar | Completed | No outcome recorded |
| Phase 1 | NCT02003573 Background | Jan 2014 → Jan 2015 | acute myeloid leukemia | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT01798901 Background | Sep 2013 → Feb 2015 | acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22), acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute promyelocytic leukemia +1 | Alison Walker | Completed | No outcome recorded |
| Phase 1 | NCT01352650 Comparator | Jun 2011 → Dec 2016 | acute myeloid leukemia | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 1 | NCT00886457 Background | Apr 2009 → Aug 2010 | cancer | Nevada Cancer Institute | Terminated | No outcome recorded |
| Phase 1/212 trials | ||||||
| Phase 1/2 | NCT03184935 Background | Dec 2026 → Jun 2027 | myelodysplastic syndrome | Sclnow Biotechnology Co., Ltd. | Suspended | No outcome recorded |
| Phase 1/2 | NCT06930651 Background | Sep 2025 → May 2028 expected | myeloid neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06383572 Background | Jun 2024 → Apr 2027 expected | myeloid neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05148234 Background | Nov 2022 → Feb 2023 | myelodysplastic syndrome | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT04061421 Background | Nov 2021 → Aug 2027 expected | myelodysplastic/myeloproliferative neoplasm | Michael Savona | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04655755 Background | Jan 2021 → Jul 2028 expected | chronic myelomonocytic leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04611711 Background | Nov → Dec 2020 | digestive system cancer | Peking University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03303339 Background | Nov 2017 → Nov 2021 | acute myeloid leukemia | Cardiff Oncology | Completed | No outcome recorded |
| Phase 1/2 | NCT03113071 Background | Jun 2017 → Jan 2019 | acute myeloid leukemia, myelodysplastic syndrome | Fox Chase Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02649790 Background | Jan 2016 → Aug 2024 | acute myeloid leukemia, castration-resistant prostate carcinoma, colorectal cancer, myelodysplastic syndrome +1 | Karyopharm Therapeutics Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT02608268 Background | Nov 2015 → Aug 2022 | cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/2 | NCT02343939 Background | Jul 2015 → Sep 2018 | acute myeloid leukemia | Gilead Sciences | Terminated | No outcome recorded |
| Phase 224 trials | ||||||
| Phase 2 | NCT07060001 Comparator | Apr 2026 → Dec 2028 expected | acute myeloid leukemia | The Methodist Hospital Research Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07148947 Background | Mar 2026 → Dec 2028 expected | myeloproliferative neoplasm | University of Washington | Recruiting | No outcome recorded |
| Phase 2 | NCT06672146 Background | May 2025 → Mar 2027 expected | acute myeloid leukemia | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT07163793 Comparator | Oct 2024 → Oct 2026 expected | acute myeloid leukemia | Northwell Health | Recruiting | No outcome recorded |
| Phase 2 | NCT06337331 Background | Aug 2024 → Aug 2026 | acute myeloid leukemia, myelodysplastic syndrome | Northside Hospital, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT06316960 Background | Mar 2024 → Mar 2026 overdue | acute myeloid leukemia, KIT gene mutation, childhood acute myeloid leukemia, core binding factor acute myeloid leukemia | Children's Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 2 | NCT06084819 Comparator | Aug 2023 → Jan 2029 expected | acute myeloid leukemia | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04878432 Background | Mar 2022 → Oct 2023 | myelodysplastic syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT04146038 Background | Oct 2020 → Oct 2021 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 2 | NCT04482621 Comparator | Sep 2020 → Jul 2026 | COVID-19 | Johns Hopkins University | Suspended | No outcome recorded |
| Phase 2 | NCT04514081 Comparator | Aug 2020 → Aug 2022 | classic Hodgkin lymphoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03946670 Background | Jun 2019 → Apr 2022 | myelodysplastic syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT03418038 Background | Mar 2018 → Feb 2031 expected | Hodgkins lymphoma, chronic myelomonocytic leukemia, clonal hematopoiesis of indeterminate potential, diffuse large B-cell lymphoma +1 | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT03417427 Comparator | Feb 2018 → Jan 2022 | myeloid leukemia | Xuejie Jiang | Unknown | No outcome recorded |
| Phase 2 | NCT02937662 Comparator | Oct 2016 → Apr 2020 | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Completed | No outcome recorded |
| Phase 2 | NCT02781883 Background | May 2016 → Dec 2027 expected | acute myeloid leukemia | Bio-Path Holdings, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT02532010 Comparator | Jun 2015 → Feb 2016 | acute myeloid leukemia | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 2 | NCT02662647 Background | Apr 2015 → Jun 2018 | acute myeloid leukemia | Chinese PLA General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01993641 Background | Dec 2013 → May 2015 | myelodysplastic syndrome | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 2 | NCT01893372 Background | Oct 2013 → Jan 2019 | leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01546038 Background | Jun 2012 → Jan 2017 | acute myeloid leukemia | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00801489 Background | Apr 2007 → Oct 2028 expected | acute myeloid leukemia, inv(16)(p13.1;q22), acute myeloid leukemia, t(16;16)(p13.1;q22), acute myeloid leukemia, t(8;21)(q22; q22.1), myelodysplastic syndrome with excess blasts | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT00321711 Comparator | Oct 2006 → Oct 2009 | myelodysplastic syndrome, thrombocytopenia | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00067808 Comparator | Oct 2003 → May 2009 | chronic myelomonocytic leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT05453552 Background | Jul 2022 → Dec 2023 | disease related to hematopoietic stem cell transplant, myelodysplastic syndrome | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05449899 Background | Jul 2022 → Dec 2023 | acute myeloid leukemia, disease related to hematopoietic stem cell transplant | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04713956 Background | Jan 2021 → Jul 2023 | disease related to hematopoietic stem cell transplant, myelodysplastic syndrome | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02472145 Background | Aug 2015 → Jan 2018 | acute myeloid leukemia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2/3 | NCT02272478 Comparator | Oct 2014 → Feb 2021 | acute myeloid leukemia, myelodysplastic syndrome | Cardiff University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02159820 Comparator | Jun 2014 → Jun 2024 | ovarian cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT01417767 Comparator | Sep 2011 → Sep 2013 | myelodysplastic syndrome | Xiao Li | Unknown | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT05883956 Comparator | Dec 2023 → Dec 2024 overdue | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Otsuka Australia Pharmaceutical Pty Ltd | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05586074 Comparator | Mar 2023 → Nov 2027 expected | acute myeloid leukemia | Sunshine Lake Pharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05382390 Background | Jan 2022 → Jan 2024 | acute myeloid leukemia | Huihan Wang | Unknown | No outcome recorded |
| Phase 3 | NCT05264883 Comparator | Mar 2021 → Jun 2023 | acute myeloid leukemia | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT04229979 Comparator | Feb 2021 → Dec 2025 overdue | acute myeloid leukemia | Sellas Life Sciences Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03926624 Comparator | Nov 2019 → Jan 2026 | acute myeloid leukemia | Delta-Fly Pharma, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02920008 Comparator | Mar 2017 → Jan 2020 | acute myeloid leukemia | Astex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02665065 Comparator | Jun 2016 → Jun 2022 overdue | acute myeloid leukemia | Actinium Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02562443 Background | Dec 2015 → Jul 2020 | myelodysplastic syndrome with excess blasts | Traws Pharma, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02348489 Comparator | Mar 2015 → May 2018 | acute myeloid leukemia | Astex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00260832 Comparator | Nov 2005 → Oct 2009 | acute myeloid leukemia | Eisai Inc. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01011283 Comparator | Nov 2009 → Jan 2011 | myelodysplastic syndrome | Eisai Inc. | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05258799 Background | Jan 2022 → Jan 2024 | acute myeloid leukemia | Huihan Wang | Unknown | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-09-19 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Astex announce that the European Commission has approved INAQOVI (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia ® otsuka.co.jp ↗ |
| 2022-08-22 | Otsuka Pharmaceutical Development & Commercialization, Inc. | European Medicines Agency commences review of oral fixed-dosecombination of decitabine and cedazuridine for the treatment ofadults with acute myeloid leukemia otsuka.co.jp ↗ |
| 2014-03-31 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Acquires Rights to Hematological Cancer Treatment Dacogen From Eisai (U.S.)® otsuka.co.jp ↗ |
| 2014-03-31 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Acquires Rights to Hematological Cancer Treatment Dacogen® (decitabine) From Eisai (U.S.) otsuka-us.com ↗ |
Evidence & citations 25 cited values
Every value below carries the sentence it was read from. 495 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Decitabine | “ABNL MARRO 001 (AM-001) is an Open label, phase 1/2 study within the framework of the ABNL-MARRO that will test novel treatment combinations in MDS/MPN. Each Arm of AM-001 will...” NCT04061421 ↗481“In the control arm, patients received other physician-directed regimen including fludarabine, cytarabine with/without granulocyte stimulating factor(FLA±G) regimen,cytarabine...” NCT02937662 ↗ “Participants will receive standard low-intensity therapy (LIT) regimens for newly diagnosed AML, which may include venetoclax combined with either azacitidine, decitabine, or...” NCT07014462 ↗ “ASTX727 is a combination of two drugs (cedazuridine and decitabine) that have been designed to target cancer cells with a PCR2 mutation and to disrupt the cells' ability to...” NCT04872543 ↗ “Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm,...” PMID 32873343 ↗ Sep 2020 “Decitabine (not allowed as a single agent with the exception of patients with documented TP53 mutations who have not previously received 10-day regimens of single agent decitabine)” NCT02665065 ↗ “HMA: Decitabine was administered at 20mg/m2/day for five consecutive days or Ara-C was administered at 75mg/m2/day for seven consecutive days.” NCT03662087 ↗ “All participants will receive ASTX727 orally (cedazuridine 100mg + 35mg decitabine) Days 0-5 prior to receiving Lutathera Day 8 +/- 2days.” NCT05178693 ↗ “A large number of studies have confirmed that demethylated drug decitabine can effectively induce tumor-specific antigen expression.” NCT04672473 ↗ “The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.” NCT01893372 ↗ “ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine.” NCT03813186 ↗ “Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients” NCT07505160 ↗ “This research study involves the study drug Inqovi, which is a combination of the drugs decitabine and cedazuridine.” NCT04980404 ↗ “Phase II Trial of Low Dose Decitabine (Dacogen) in Patients With Primary Myelofibrosis and Post ET/PV Myelofibrosis” NCT00630994 ↗ “decitabine at 5 mg/m² per day for 5 consecutive days, with a 28-day cycle (preferred for those with TP53 mutations)” NCT06612944 ↗ “Patients will receive salvage treatment of PD-1 inhibitor Tislelizumab combined with decitabine for four cycles” NCT05137886 ↗ “Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation” NCT01483274 ↗ “Patients will receive best supportive care (BSC): azacitidine (AZA) and/or decitabine (DAC) are permitted.” NCT02562443 ↗ “On day 1 of each cycle, decitabine 75 mg/m2 will be given subcutaneously, and will continue for 5 days.” NCT05282719 ↗ “treated with cycle 2-6 R-CHOP in combination with obutinib or decitabine or lenalidomide or Chidamide.” NCT06748521 ↗ “35 mg decitabine/100 mg cedazuridine taken by mouth once daily on Days 1, 2, 3 of a 28 day cycle.” NCT04742634 ↗ “Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)” NCT04953897 ↗ “Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)” NCT04953910 ↗ “Decitabine is being administered i.v. Azacitidine is being administered i.v or s.c.” NCT03946670 ↗ “Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia” NCT01794702 ↗ “ASTX727 is a combination drug of 35 mg decitabine and 100 mg cedazuridine.” NCT02649790 ↗ “Low intensity: low dose cytarabine (LDAC), decitabine, or azacitidine.” NCT02920008 ↗ “ASTX727 is made up of the 2 study drugs cedazuridine and decitabine.” NCT03922555 ↗ “Decitabine (alternative to azacitidine) Injectable 20 mg/m² per day” NCT07451912 ↗ “20 mg/m\^2 decitabine given as a 1-hour intravenous (IV) infusion” NCT02348489 ↗ “azacitidine 75 mg/m2 for 7 days or decitabine 20mg/m2 for 5 days” NCT01902329 ↗ “Self-administration of VTD-101 ointment (Decitabine ointment)” NCT05717621 ↗ “Decitabine 10mg/m2 ivgtt D-5 to-1 if with TP53 gene muation” NCT04480099 ↗ “Venetoclax+hypomethylating agent (decitabine, azacitidine)” NCT06713837 ↗ “decitabine 20mg/m2 intravenously daily for 5 days (d1-d5)” NCT03985007 ↗ “one course of Decitabine (5-aza-deoxycytidine,Dacogen)” NCT01417767 ↗ “D: Decitabine(15mg/m2) d1-5 G: G-CSF（300ug/d） d0-9” NCT04168138 ↗ “Oral 250 mg THU and 5 mg decitabine Once per week” NCT04055818 ↗ “Decitabine 20mg/m2 IV day 1-5, every 28 days” NCT03395873 ↗ “oral decitabine (LD) + cedazuridine (E7727)” NCT03502668 ↗ “Decitabine (DAC): 10 mg/m2/day IV (Mon-Fri)” NCT01241162 ↗ “Decitabine 20 mg/m2 IV over 1 hr days 1-5” NCT00740181 ↗ “Decitabine, 20 mg/m2/d, IV, on days 1-5” NCT04541277 ↗ “cytarabine OR azacitidine OR decitabine” NCT03236857 ↗ “Decitabine (DEC):20mg/m²/day, Day 2-4” NCT07117422 ↗ “decitabine (15 mg/m2 daily, days 1-5)” NCT05258799 ↗ “Daunorubicin HCl Decitabine Erlotinib” NCT02551718 ↗ “Decitabine: 25mg, IV drip, days 1-3” NCT06651866 ↗ “Daunorubicin, Decitabine, Docetaxel” NCT02788201 ↗ “oral decitabine 5mg + cedazuridine” NCT03906695 ↗ “Decitabine (trade name Dacogen)” NCT03771222 ↗ “Decitabine(20mg/m2,days 1 to 5)” NCT06084819 ↗ “Decitabine 10 mg/m2 D-5 - -1” NCT06750991 ↗ “Decitabine and Cedazuridine” NCT06802146 ↗ “cedazuridine + decitabine” NCT04155580 ↗ “Decitabine 20mg/m2 d8-12” NCT03453255 ↗ “Decitabine” NCT01194908 ↗ “Decitabine” NCT02272478 ↗ |
| Known as | 2'-deoxy-5-azacytidine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201129 ↗ |
| Known as | 5-aza-2 deoxycytidine | “The goal of this clinical research study is to learn if giving 5-aza-2 deoxycytidine (decitabine) in combination with Mylotarg (gemtuzumab ozogamicin) can help to control AML...” NCT00968071 ↗9“Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases.” PMID 30962963 ↗ Mar 2019 “There are mechanistic reasons to believe that the DNA methyltransferase inhibitor 5-aza-2 -deoxycytidine (decitabine) can more potently increase HbF.” NCT01375608 ↗ “Decitabine (5 aza-2'deoxycytidine), a drug that produces marked DNA hypomethylator, has demonstrated antileukemic activity at low doses.” NCT00075010 ↗ “Inhibition of DNA Methylation by 1-hr Infusion of 5-aza-2'-Deoxycytidine (Decitabine) x 10 Days” NCT00886457 ↗ “5-Aza-2'-deoxycytidine (decitabine; DAC) is a DNA hypomethylating agent” PMID 10694544 ↗ Mar 2000 “decitabine (5-aza-2'deoxycytidine)” NCT00041990 ↗ “decitabine (5-aza-2'deoxycytidine)” NCT00043381 ↗ “decitabine (5-aza-2'deoxycytidine)” NCT00042003 ↗ “decitabine (5-aza-2'deoxycytidine)” NCT00042016 ↗ |
| Known as | 5-aza-2\'deoxycytidine | “The investigators have shown that the DNA methylation inhibitor 5-aza-2\'deoxycytidine (Decitabine), but not 5-azacytidine, induced HIV expression in vitro.” NCT05230368 ↗ |
| Known as | 5-aza-4'-thio-2'- deoxycytidine | “The nucleoside analog 5-aza-4'-thio-2'- deoxycytidine (Aza-TdC) is incorporated into DNA” NCT03366116 ↗ |
| Known as | 5-aza-deoxycytidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01417767 ↗ |
| Known as | Aza-TdC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03366116 ↗ |
| Known as | DAC | “A phase I study utilizing decitabine (DAC) followed by the mammalian target of rapamycin (mTOR) inhibitor, rapamycin, in patients with relapsed/refractory adult AML was...” PMID 24138944 ↗ Sep 201322“Decitabine (DAC), one major DNA demethylating agent, has been approved for treatment of preleukemic hematological disease myelodysplastic syndrome (MDS) by the Food and Drug...” NCT02159820 ↗ “Although decitabine (DAC) shows activity against myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), patient responses are limited, and prognoses remain poor.” PMID 40453133 ↗ Jan 2025 “Approval of decitabine (DAC) in the European Union (EU) in 2012 for the treatment of patients with AML ≥65 years” PMID 26008690 ↗ May 2015 “Decitabine (DAC), a demethylating agent, is known to promote cell differentiation and maturation at low doses.” PMID 25566808 ↗ Jan 2015 “Patients will receive best supportive care (BSC): azacitidine (AZA) and/or decitabine (DAC) are permitted.” NCT02562443 ↗ “Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days.” NCT02214407 ↗ “We conducted a phase 2 trial of decitabine (DAC) in 39 patients with advanced CMML.” PMID 21828134 ↗ Aug 2011 “5-Aza-2'-deoxycytidine (decitabine; DAC) is a DNA hypomethylating agent” PMID 10694544 ↗ Mar 2000 “Decitabine (DAC) was administered at 20mg/m2/day on days -10 to -8.” NCT07052422 ↗ “Decitabine (DAC): 20mg/m2 intravenous for 1 hour daily (d1 to d5);” NCT05264883 ↗ “using decitabine (DAC) (20mg/m2 for five days) based chemotherapy” PMID 28881839 ↗ Aug 2016 “TQB2618 injection azacitidine, AZA decitabine, DAC” NCT05426798 ↗ “Decitabine (DAC) may reverse the DNA changes.” NCT02839694 ↗ “DNA demethylating agent, Decitabine (DAC).” NCT00037817 ↗ “the hypomethylating agent decitabine (DAC)” PMID 30102945 ↗ Aug 2018 “Azacitidine (AZA) or Decitabine (DAC)” NCT07238686 ↗ “Decitabine (DAC)” NCT03233724 ↗ “Decitabine (DAC)” NCT05453552 ↗ “Decitabine (DAC)” NCT04713956 ↗ “Decitabine (DAC)” NCT05449899 ↗ “Decitabine (DAC)” NCT00002831 ↗ “Decitabine (DAC)” NCT06686108 ↗ |
| Known as | Dacogen | “A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia” NCT01853228 ↗6“Dacogen™ (decitabine) is a FDA approved drug (NDA - 021790) for the treatment of myelodysplastic syndromes (MDS)” NCT00879385 ↗ “Decitabine (trade name Dacogen®) is a cytidine deoxynucleoside analogue” NCT03080766 ↗ “Decitabine (Dacogen)” NCT01378416 ↗ |
| Known as | DACOGEN (Decitabine) | “DACOGEN (Decitabine)” NCT01876641 ↗1“Dacogen (decitabine)” NCT01011283 ↗ |
| Known as | DEC | “1.2 AZA (DEC) + DLI For patients with TP53 mutations or those who do not respond to VEN, subcutaneous injection of azacitidine at 32 mg/m² per day for 5 consecutive days, with...” NCT06612944 ↗6“The goal of this clinical trial is to learn about the safety and effectiveness of the combination drug Tetrahydrouridine (THU) and decitabine (DEC) to treat patients with...” NCT07006025 ↗ “Decitabine/cedazuridine (DEC/CED) (a nucleoside metabolic inhibitor and cytidine deaminase inhibitor).” NCT06802146 ↗ “Phase II Study on Venetoclax (VEN) Plus Decitabine (DEC) (VEN-DEC) for Elderly” NCT04476199 ↗ “decitabine (Dec) (2.5 mg) and tetrahydrouridine (THU) (125 mg) minitablets” NCT07435636 ↗ “decitabine (DEC), a DNA methyltransferase 1 inhibitor” PMID 41161613 ↗ Oct 2025 “Decitabine (DEC):20mg/m²/day, Day 2-4” NCT07117422 ↗ |
| Known as | Decitabina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201129 ↗ |
| Known as | decitabine (DAC) | “decitabine (DAC)” NCT01707004 ↗ |
| Known as | Decitabine (Dacogen, 5-aza-2-deoxycytidine) | “Decitabine (Dacogen, 5-aza-2-deoxycytidine)” NCT05362942 ↗ |
| Known as | Decitabine (trade name Dacogen or 5-aza-2'-deoxycytidine/DAC | “Decitabine (trade name Dacogen or 5-aza-2'-deoxycytidine/DAC” NCT01241162 ↗ |
| Known as | Decitabine (trade name Dacogen) | “Decitabine (trade name Dacogen)” NCT03771222 ↗ |
| Known as | Decitabine component of astx-727 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201129 ↗ |
| Known as | Decitabine component of inqovi | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201129 ↗ |
| Known as | NSC-127716 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201129 ↗ |
| Known as | VTD-101 | “Self-administration of VTD-101 ointment (Decitabine ointment)” NCT05717621 ↗ |
| Action | Inhibit | “Decitabine is a new drug that blocks DNA methylation.” NCT00398983 ↗1“DNA (cytosine-5)-methyltransferase 3A inhibitor” CHEMBL1201129 ↗ |
| Modality | Small molecule | “the cytosine analog decitabine” PMID 21700776 ↗ Jun 2011 |
| Route | Intravenous | “IV over 4 hours on days -8 and -7” NCT00002831 ↗ |
| Target | DNMT1 | “deplete DNA methyltransferase 1 (DNMT1)” PMID 21700776 ↗ Jun 2011 |
| Target | DNMT3A | “DNA (cytosine-5)-methyltransferase 3A inhibitor” CHEMBL1201129 ↗ |